Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Tecnología para la monitorización y control de Diabetes

Resultados 136 resultados
LastUpdate Última actualización 21/02/2026 [06:55:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
Resultados 1 a 25 de 136 nextPage  

ASSEMBLY FOR SECURING A GLUCOSE MONITORING DEVICE AND RELATED TECHNIQUES

NºPublicación:  WO2026039036A1 19/02/2026
Solicitante: 
SANVITA MEDICAL CORP [US]
SANVITA MEDICAL CORPORATION
WO_2026039036_PA

Resumen de: WO2026039036A1

An assembly for securing a glucose monitoring device and related techniques are disclosed. The assembly may include a retainer member configured to fit loosely over the glucose monitoring device without attaching or connecting to it. To that end, the retainer member and a housing of the glucose monitoring device may include respective interfacing features configured to interface with one another. The assembly further may include an adhesive overpatch configured to adhere to the retainer member and the user's skin without adhering to the glucose monitoring device. In accordance with some embodiments, removal of the adhesive overpatch from the user's skin may effectuate simultaneous removal of the retainer member from the glucose monitoring device without compromising adhesion of the glucose monitoring device to the user's skin or disrupting placement of its implanted sensor.

BLOOD GLUCOSE ESTIMATION USING NEAR INFRARED LIGHT EMITTING DIODES

NºPublicación:  AU2026200301A1 19/02/2026
Solicitante: 
MEDWATCH TECHNOLOGIES INC
MEDWATCH TECHNOLOGIES, INC
AU_2026200301_A1

Resumen de: AU2026200301A1

Abstract Near Infrared Spectroscopy is employed to non-invasively detect blood glucose concentrations, in a multi-sensing detection device. A multi-layered artificial neural network is used to assess these relationships of non-linear interference from human tissue, as well as differences among individuals, and accurately estimate blood glucose levels. Diffuse reflectance spectrum from tlle palm at six different wavelengths analyzed with a neural network, results in a correlation coefficient as high as 0. 9216 when compared to a standard electrochemical glucose analysis test.

DEVICE FOR DELIVERING INSULIN HAVING FILM AND TOP ENCLOSURE DEFINING RESERVOIR

NºPublicación:  US20260048196A1 19/02/2026
Solicitante: 
AITA BIO INC [US]
AITA BIO INC
US_20260048196_PA

Resumen de: US20260048196A1

A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.

DEVICE FOR DELIVERING INSULIN HAVING FILM AND TOP ENCLOSURE DEFINING RESERVOIR

NºPublicación:  WO2026039326A1 19/02/2026
Solicitante: 
AITA BIO INC [US]
AITA BIO INC
WO_2026039326_PA

Resumen de: WO2026039326A1

A device is disclosed for delivering medication to a user. The device comprises first and second enclosures that together form a housing of the device, the housing configured to house a reservoir for storing the medication, wherein the first enclosure includes an inner wall of the housing; and a film joined to the inner wall of the first enclosure, wherein the film and the inner wall of the first enclosure are configured to form walls of the reservoir for storing the medication.

ELECTRONIC DEVICE, METHOD, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM FOR TAGGING PERSONALIZED BLOOD GLUCOSE PATTERN

NºPublicación:  WO2026038662A1 19/02/2026
Solicitante: 
SAMSUNG ELECTRONICS CO LTD [KR]
\uC0BC\uC131\uC804\uC790\uC8FC\uC2DD\uD68C\uC0AC
WO_2026038662_A1

Resumen de: WO2026038662A1

This electronic device may receive continuous blood glucose data about a user. Sensing data for identifying the state of the user may be received. The state of the user may include an activity state of the user and a biometric state of the user. The sensing data may include exercise information related to the activity state and biometric information related to the biometric state. Blood glucose patterns may be identified in time intervals in which the activity state and/or the biometric state is identified on the basis of the continuous blood glucose data and the sensing data. A personalized blood glucose pattern may be identified from the blood glucose patterns in the time intervals. The personalized blood glucose pattern may include a pattern in which blood glucose is changed according to the state. A visual object indicating that the personalized blood glucose pattern is identified by the state in a graph representing the continuous blood glucose data may be displayed through a display.

SYSTEMS, DEVICES, AND METHODS TO COMPENSATE FOR TEMPERATURE EFFECTS ON SENSORS

NºPublicación:  US20260047785A1 19/02/2026
Solicitante: 
DEXCOM INC [US]
Dexcom, Inc
US_20260047785_PA

Resumen de: US20260047785A1

This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.

WEARABLE TRANSPLANTABLE TISSUE VIABILITY BIOSENSOR

NºPublicación:  US20260047780A1 19/02/2026
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California
US_20260047780_PA

Resumen de: US20260047780A1

Disclosed are miniaturized, wearable microneedle biosensor devices, systems, and methods for measuring intradermal concentrations of various metabolites (including but not limited to lactate, pyruvate, and/or glucose) in order to directly assess the viability of living tissue (e.g., human or other mammalian soft tissue). In a variety of implementations, for example, the disclosed microneedle biosensor devices are self-contained in terms of power source, sample acquisition, measurement, and data transmission capabilities, e.g., allowing it to function autonomously once placed. In some implementations, for example, the disclosed microneedle biosensor devices can assess the viability of soft tissue (e.g., skin with or without fat, fascia, or muscle) during and after reconstructive surgery in which soft tissue is repositioned, rotated, or transferred to another site in the body (including but not limited to both microvascular free tissue transfer and regional pedicled flaps).

POROUS MICRONEEDLE ARRAY-BASED INTERSTITIAL FLUID GLUCOSE DETECTION DEVICE, METHOD OF PREPARING POROUS MICRONEEDLE ARRAY WITH POROSITY GRADIENT, AND METHOD OF PREPARING COLORIMETRIC FILM

NºPublicación:  US20260047781A1 19/02/2026
Solicitante: 
WUHAN UNIV [CN]
WUHAN UNIVERSITY
US_20260047781_PA

Resumen de: US20260047781A1

A porous microneedle array-based interstitial fluid glucose detection device includes a microneedle module, a colorimetric detection module, an electrochemical detection module, and a liquid transport layer. The microneedle module includes a porous microneedle array with a porosity gradient, the porosity gradually increases from the needle tip to the microneedle substrate; the porous microneedle array penetrates human epidermis and extract interstitial fluid, which is then transferred to both the colorimetric detection module and the electrochemical detection module via the liquid transport layer. Within the colorimetric detection module, glucose undergoes a reaction with the color on the colorimetric film, resulting in color development that enables rapid glucose detection; In the electrochemical detection module, glucose undergoes a redox reaction on the working electrode, resulting in the generation of a current signal for the accurate detection of glucose.

SYSTEMS AND METHODS FOR CONTINUOUS GLUCOSE MONITORING OUTCOME PREDICTIONS

NºPublicación:  EP4695821A1 18/02/2026
Solicitante: 
WELLDOC INC [US]
Welldoc, Inc
CN_121263852_PA

Resumen de: AU2024252061A1

Methods and devices include predicting future glucose and engagement levels for a user by receiving the user's glucose levels collected by a continuous glucose monitoring (CGM) device over a time period, receiving engagement data associated with the user, wherein the engagement data are associated with the user's medication intake, diet, physical activity, laboratory results, and education activity, determining a first glycemia risk index (GRI) value, determining, using a machine learning model and responsive to the user's glucose levels and the engagement data collected over the time period, one or more predictions for future glucose levels for the user including a prediction that a future GRI value is greater than or less than the first GRI value, and determining, using the machine learning model and responsive to the user's engagement data collected over the time period, one or more predictions for future engagement levels.

SYSTEMS AND METHODS FOR MONITORING AND TREATING DIABETIC FOOT ULCERS

NºPublicación:  EP4696226A2 18/02/2026
Solicitante: 
SMITH & NEPHEW [GB]
T.J. Smith & Nephew, Limited
EP_4696226_PA

Resumen de: EP4696226A2

In some aspects, a computer-implemented method is disclosed for gathering and processing sensor data to identify a risk of impacting or causing a skin injury. The computer-implemented method can include: receiving, via a computer network, sensor feature data representing output of a user sensor configured to be worn on a limb of a user; generating activity classification model output data using the sensor feature data and an activity classification model, the activity classification model output data representing likelihoods that the sensor feature data corresponds to each of a plurality of different activity classifications; determining an activity classification from the activity classification model output data; and transmitting, via the computer network, display data representing the activity classification to a computing device configured to present the display data.

DRUG DELIVERY DEVICE WITH INTEGRATED OPTICAL-BASED GLUCOSE MONITOR

NºPublicación:  EP4696344A2 18/02/2026
Solicitante: 
INSULET CORP [US]
Insulet Corporation
EP_4696344_PA

Resumen de: EP4696344A2

Embodiments of the present disclosure relate to approaches for more efficiently measuring glucose levels using a wearable drug delivery device. In some embodiments, the wearable drug delivery device may include a needle deployment component including a cannula and an optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user. The wearable drug delivery device may further include a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit.

CONTINUOUS BLOOD GLUCOSE MEASUREMENT APPARATUS

NºPublicación:  ES3055463T3 12/02/2026
Solicitante: 
I SENS INC
i-Sens, Inc
EP_4656127_PA

Resumen de: EP4656127A2

The present invention relates to a continuous blood glucose measurement apparatus which, by manufacturing a body-attachable unit in an assembled state inside an applicator, minimizes the additional work by a user for attaching the body-attachable unit to the body and thus enables the body-attachable unit to be attached to the body simply by means of operating the applicator, and, by providing a wireless communication chip on the body-attachable unit and enabling communication with an external terminal, can be used in a simple and convenient manner without the additional work of connecting a separate transmitter and enables easier maintenance and management, and, by having the operation of the body-attachable unit initiated by means of the user's manipulation after being attached to the body, enables the operation initiation point to be adjusted to an appropriate point as necessary by the user, enables an operation initiation in a stabilized state and thus enables more accurate blood glucose measurement.

METHOD OF COMPENSATING FOR INSULIN RESERVOIR FRICTION DURING INSULIN THERAPY

NºPublicación:  US20260041847A1 12/02/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
US_20260041847_PA

Resumen de: US20260041847A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate in strokes to drive a plunger within a reservoir in a fluid delivery device, the motor rotation data indicating time intervals between changes of position of the motor; for each stroke of a first plurality of strokes of the motor, determining an instantaneous delivery rate during one or more steps of the stroke based on the motor rotation data, and storing the instantaneous delivery rate to a buffer; determining a pre-compensation delivery rate of the fluid delivery device based on data in the buffer; and determining, in response to the pre-compensation delivery rate being lower than a pre-determined delivery rate, a first adjustment to at least one of a motor drive voltage level or a motor drive duty cycle of a drive signal of the motor.

METHOD OF SENSOR-LESS PLUNGER DETECTION DURING INSULIN RESERVOIR SETUP

NºPublicación:  US20260041843A1 12/02/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC
US_20260041843_PA

Resumen de: US20260041843A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.

Apparatus and Method for Taking Blood Glucose Measurements and Recommending Insulin Doses

NºPublicación:  US20260041338A1 12/02/2026
Solicitante: 
HYGIEIA INC [US]
Hygieia, Inc
US_20260041338_PA

Resumen de: US20260041338A1

The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods.

CELL THERAPY FOR PATIENTS

NºPublicación:  US20260041337A1 12/02/2026
Solicitante: 
YANG DEMAO [US]
Yang Demao
US_20260041337_PA

Resumen de: US20260041337A1

Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.

NON-INTRUSIVE, NEEDLE-FREE DETECTION OF THE SEVERE HYPOGLYCEMIA ONSET

NºPublicación:  US20260041379A1 12/02/2026
Solicitante: 
LANDAU ALEXANDER [US]
LANDAU IGOR [US]
Landau Alexander,
Landau Igor
US_20260041379_A1

Resumen de: US20260041379A1

Method for non-intrusive, needle-free detection of severe hypoglycemia onset through assessment of the cerebral arteriovenous oxygen difference. The method primarily pertains to the treatment of high-risk younger patients with Type 1 Diabetes Mellitus (T1DM) experiencing nocturnal hypoglycemia in order to prevent so called “Death in Bed” syndrome-the sudden death of young diabetic patients without any history of long-term complications.

NON-INVASIVE BIOSIGNAL MEASUREMENT DEVICE AND METHOD BASED ON SKIN EFFECT REMOVAL

NºPublicación:  US20260041375A1 12/02/2026
Solicitante: 
KOREA I T S CO LTD [KR]
Korea I. T. S. Co., Ltd
US_20260041375_PA

Resumen de: US20260041375A1

A non-invasive biosignal measurement device based on skin effect removal, includes: a signal measurement instrument measuring a PPG signal of a measurement subject in contact with the skin on one side of a specific body part of the measurement subject; a signal reception unit receiving the PPG signal from the signal measurement instrument; and a ratio value calculation unit removing noise due to a skin effect from the PPG signal, and then calculating ratio values at different wavelengths for measuring a biosignal including blood sugar and glycated hemoglobin of the measurement subject. The signal measurement instrument includes a first sensor module including an optical barrier and a second sensor module for removing the skin effect.

METHOD FOR CONTINUOUSLY MEASURING BLOOD GLUCOSE USING A SENSOR MODULE, AND MEDICAL DEVICE MANAGEMENT SYSTEM USING THE SAME

NºPublicación:  WO2026034834A1 12/02/2026
Solicitante: 
SD BIOSENSOR INC [KR]
SD BIOSENSOR, INC
WO_2026034834_PA

Resumen de: WO2026034834A1

Disclosed is a sensor module management system comprising a sensor module including a transcutaneous analyte sensor configured to perform a measurement indicating an analyte level and a sensor electronics unit communicatively connected to the transcutaneous analyte sensor, and a mobile device configured to wirelessly communicate with the sensor electronics unit. The sensor module is configured to, when it is confirmed that a command array included in a sub-advertisement event received from the mobile device includes a first command designating a group ID to which the sensor module belongs and a device ID of the sensor module, transmit a first response to the mobile device in response to the first command. The first response includes the analyte level.

METHOD OF SENSOR-LESS PLUNGER DETECTION DURING INSULIN RESERVOIR SETUP

NºPublicación:  EP4691517A1 11/02/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
EP_4691517_PA

Resumen de: EP4691517A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate steadily to actuate a drive system for driving a plunger of a reservoir in a fluid delivery device; for each rotation of a plurality of rotations of the motor, based on a measured rotation time of the rotation of the motor and a previous maximum rotation time of the motor, determining a current maximum rotation time of the motor and storing the current maximum rotation time in a buffer; determining a coefficient of variation of motor rotation time based on data in the buffer; determining a change of the coefficient of variation of motor rotation time with respect to a baseline coefficient of variation of motor rotation time; and determining whether the plunger is detected based on a comparison of the change and a threshold value.

METHOD OF COMPENSATING FOR INSULIN RESERVOIR FRICTION DURING INSULIN THERAPY

NºPublicación:  EP4693324A1 11/02/2026
Solicitante: 
MEDTRONIC MINIMED INC [US]
Medtronic MiniMed, Inc
EP_4693324_PA

Resumen de: EP4693324A1

A processor-implemented method includes obtaining motor rotation data associated with a motor that is configured to rotate in strokes to drive a plunger within a reservoir in a fluid delivery device, the motor rotation data indicating time intervals between changes of position of the motor; for each stroke of a first plurality of strokes of the motor, determining an instantaneous delivery rate during one or more steps of the stroke based on the motor rotation data, and storing the instantaneous delivery rate to a buffer; determining a pre-compensation delivery rate of the fluid delivery device based on data in the buffer; and determining, in response to the pre-compensation delivery rate being lower than a pre-determined delivery rate, a first adjustment to at least one of a motor drive voltage level or a motor drive duty cycle of a drive signal of the motor.

ACCURATE PREDICTION OF QUANTITY AND TIMING OF INSULIN RESERVOIR REFILLS

NºPublicación:  EP4693326A2 11/02/2026
Solicitante: 
INSULET CORP [US]
Insulet Corporation
EP_4693326_PA

Resumen de: EP4693326A2

Exemplary embodiments may provide an improved approach to automated insulin delivery by more accurately estimating the total daily insulin (TDI) of a user. As a result, less insulin is wasted by the delivery system, and the estimate of TDI more closely matches a user's actual daily insulin needs. Hence, the user need not refill the insulin reservoir excessively or need not fret unnecessarily about running out of insulin prematurely. The estimate relies on the history of actual automated insulin deliveries and thus reflects the actual insulin delivered to the user more accurately than conventional approaches.

MANAGEMENT PROCESS FOR INSULIN THERAPY USING REINFORCEMENT LEARNING AND THERAPY ESCALATION PATHWAYS

NºPublicación:  EP4687666A2 11/02/2026
Solicitante: 
BIGFOOT BIOMEDICAL INC [US]
Bigfoot Biomedical, Inc
CN_121099951_PA

Resumen de: AU2024252324A1

A method of therapy escalation for patients with diabetes includes receiving glucose data of a user from an in vivo glucose monitoring device, receiving first therapy information of a first therapy, wherein the first therapy includes basal insulin, calculating one or more glucose metrics based on the received glucose data, titrating a dose of the basal insulin based on the one or more glucose metrics, and determining overbasalization based on one or more of the glucose data and the first therapy information. Advantageously the system can regularly monitor glucose control of a user, detect overbasalization, provide frequent therapy intervention and adjustment, decrease a duration of intervention, and increase user adherence, outcomes, and satisfaction.

COMPUTER-IMPLEMENTED METHODS FOR PREDICTING GLUCOSE VALUES, DATA PROCESSING SYSTEM, AND APP

NºPublicación:  EP4690225A1 11/02/2026
Solicitante: 
HOFFMANN LA ROCHE [CH]
ROCHE DIABETES CARE GMBH [DE]
IBM [US]
F. Hoffmann-La Roche AG,
Roche Diabetes Care GmbH,
International Business Machines Corporation
US_20260013800_PA

Resumen de: US20260013800A1

A computer-implemented method and system for predicting and displaying glucose values, including receiving CGM data, determining, based on the data, a plurality of first predicted glucose values (33) for a first prediction time window (30), determining, based on the data, that a hypoglycemia event is predicted to occur during a second prediction time window (31) which has a contemporaneous beginning with the first prediction time window (30) but is shorter than the first window (30), and determining a plurality of second predicted glucose values (34) for the second prediction time window (31) and displaying the plurality of second predicted glucose values (34) for the second prediction time window (31) while not displaying predicted glucose values subsequent to the second prediction time window (31).

COMPUTER-IMPLEMENTED METHODS FOR PREDICTING GLUCOSE VALUES, DATA PROCESSING SYSTEM, MEDICAL SERVER, AND USER DEVICE

Nº publicación: EP4690226A1 11/02/2026

Solicitante:

HOFFMANN LA ROCHE [CH]
ROCHE DIABETES CARE GMBH [DE]
IBM [US]
F. Hoffmann-La Roche AG,
Roche Diabetes Care GmbH,
International Business Machines Corporation

US_20260013801_PA

Resumen de: US20260013801A1

Methods for predicting glucose values which involve determining a predicction time window using historical data indicative of glucose level influencing events of a person having diabetes and at least one predicted glucose level influencing event. Further disclosed are data processing systems for predicting glucose values, medical servers, user devices, and computer programs.

traducir